In a year where ADC deals have showed no signs of slowing, Solve has become the latest biotech to unlock an extra slice of capital.

A multi-level assessment of the relevance of 18 highly conserved neural zebrafish microexons showed that individual deletions of most microexons did not exhibit strong phenotypes, likely because of ...